Lung wash and tumor fluid markers for sarcoma lung metastases
Official title: Prospective Study of Biomarkers Derived From Bronchoalveolar Lavage Fluid to Predict Outcomes in Soft-Tissue Sarcomas
Run by University Health Network, Toronto · NCT06815666 · Data updated 2026-11-12
This study will test whether lung wash (bronchoalveolar lavage) and tumor fluid biomarkers can indicate how much metastatic soft tissue sarcoma is in the lungs for adults having lung surgery.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | University Health Network, Toronto Academic / other |
| Locations | 1 site (Toronto, Ontario) |
| Status | Recruiting |
| Started | January 29, 2025 |
| Main results expected | April 1, 2032 |
| Study ends | April 1, 2032 |
| Registry record updated | March 4, 2026 |
| Trial ID | NCT06815666 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age ≥18) with diagnosed soft tissue sarcoma who are undergoing resection of a lung lesion and can give informed consent are the intended participants.
✕Probably not a fit
Patients who are not undergoing bronchoscopy or lung metastasectomy, or those with a recent other invasive cancer (within 2 years, except treated non-melanoma skin cancer), would not be eligible and may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-center, Phase II prospective study will collect bronchoalveolar lavage fluid (BALF) and TA samples during routine bronchoscopy at Toronto General Hospital and obtain tissue from lung metastases and adjacent normal lung at the time of resection. Researchers will analyze those fluids and tissues to identify biomarkers and correlate their levels with metastatic burden. Sample collection is performed alongside standard clinical procedures to minimize additional interventions. The goal is to determine whether these biomarkers reliably reflect the extent of lung metastases in soft tissue sarcoma patients.
Why it matters
Potential benefit: If successful, the biomarkers could provide a less invasive way to monitor lung metastatic burden and help guide personalized follow-up or treatment decisions.
How similar studies have gone: While BAL fluid biomarkers have been explored in lung cancer and inflammatory lung diseases, applying BALF and TA biomarkers specifically to measure metastatic burden in soft tissue sarcoma is relatively novel and not yet well established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥ 18 years 2. Ability to understand and willingness to sign a written informed consent document 3. Diagnosed with soft tissue sarcoma 4. Undergoing resection of lung lesion as part of standard care Exclusion Criteria: 1\. History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for ≥ 2 years
Where it's running
-
Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network
Toronto, Ontario, Canada Recruiting
Study contacts
- Study coordinator: David Shultz
- Email: david.shultz@uhn.ca
- Phone: 416-946-4501
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Strasbourg pST soft tissue sarcoma care patterns and survival
This study looks back at how closely soft tissue sarcoma care in Strasbourg followed international guidelines and whether that related to overall survival, comparing patient care from 2010-2016 to 2017-2024.
-
Lifileucel (Tumor-infiltrating lymphocytes) for advanced soft tissue sarcoma
This study tests lifileucel, a cell therapy made from a patient’s own tumor cells, in adults with unresectable or metastatic soft tissue sarcoma who have had prior treatments to see if it helps shrink tumors and improve outcomes.
-
AYA Sarcoma Survivors: Personalized Exercise Program Pilot
This pilot tests a personalized 12-week exercise program for adolescents and young adults with sarcoma to see if a triage tool can connect them with the right rehabilitation and exercise services.
-
Neoantigen Vaccine SarVac With Tumor-Specific Lymphocytes Plus PD-1 Blocker for Advanced Sarcoma
This trial tests a personalized cancer vaccine called SarVac, given with a PD-1 blocker, and possibly tumor-specific lymphocytes, to see if it is safe and can help people with advanced soft tissue or bone sarcoma.
-
First-in-human imaging study of 68Ga-DFC413 and comparison with 68Ga-NNS309 in solid tumors
This study tests a new radioactive imaging agent, 68Ga-DFC413, to see how it behaves in patients with several solid tumors and compares it to 68Ga-NNS309.
-
Cryoablation plus anti-PD-1 therapy for advanced soft tissue sarcoma
This study tests whether freezing tumors and giving camrelizumab can help people with advanced soft tissue sarcoma after standard treatments have failed.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.